Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), ...

There is a simple discount patient access scheme for eplontersen. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Market.AccessUK ...

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

(MENAFN- Caribbean News Global) LONDON, England – The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainua) to treat adults with polyneuropathy associated ...

Eplontersen is significant for being self-administrable via ... Drug with High Potency and Long Duration – Inhibition of Factor XI (FXI) using a GalNAc-siRNA Conjugate – Ribocure Pharmaceuticals The ...

Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to eplontersen for the treatment of adult patients with transthyretin-mediated amyloid cardiomyopathy ...

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis ...

Eplontersen is a transthyretin-directed antisense oligonucleotide (ASO) designed to reduce the production of TTR protein. It is covalently linked to a ligand containing three N-acetyl galactosamine ...